

IN THE CLAIMS:

1-3 (Previously canceled).

4. (Currently amended) An isolated multimeric Mts1 protein complex, comprising at least three ~~Mts1 protein~~ molecules of an Mts1 protein.

5. (Original) The isolated multimeric Mts1 protein complex of claim 4, having a Mw in the range of about 30 kD to about 200 kD.

6. (Currently amended) The isolated multimeric Mts1 protein complex of claim 4, wherein ~~the said Mts1 protein molecule~~ is a wild type Mts1 protein.

7. (Currently amended) ~~The~~ An isolated multimeric Mts1 protein complex ~~of claim 4,~~ wherein ~~the Mts1 protein molecule~~ is comprising at least three molecules of Mts1-del75.

8. (Currently amended) The isolated multimeric Mts1 protein complex of claim 4, wherein ~~the said~~ said Mts1 protein ~~molecule~~ is of a mammalian origin.

9. (Previously canceled).

10. (Original) A pharmaceutical composition comprising the isolated complex of claim 4, and a pharmaceutically acceptable carrier.

11. (Previously amended) The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is liquid, semi-solid, or solid.

12. (Previously amended) The pharmaceutical composition of claim 10, further comprising a neurotropic factor.

13. (Original) The pharmaceutical composition of claim 12, wherein said neurotropic factor is selected from the group consisting of bFGF, aFGF, CNTF, NGF, BDNF, GDNF, NT3, NT4/5, IGF-1 and IGF-II.

14-25 (Currently canceled).

26. (New) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein is a human Mts-1 protein.

27. (New) The isolated multimeric Mts1 protein complex of claim 26, wherein said human Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 1.

28. (New) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 2.

29. (New) An isolated multimeric Mts1 protein complex, comprising at least three molecules of human Mts1-del75.